||Recombinant Human DLL1 (Accession # AAG09716) was produced in Mouse myeloma cell line, NS0-derived.
|Predicted N Terminal:
||Ser22 & His152
||Lyophilized from a 0.2 µm filtered solution in PBS.
||Measured by the ability of the immobilized protein to enhance BMP-2 induced alkaline phosphatase activity in C3H10T1/2 mouse embryonic fibroblast cells. Nobta, M. et al. (2005) J. Biol. Chem. 280:15842.The ED50 for this effect is typically 0.25 - 1.0 µg/mL.
||Recombinant Human DLL1 has a calculated MW of 57 kDa and 43 kDa. In SDS-PAGE migrates as 66 kDa and 55 kDa, reducing conditions.
||>90%, by SDS-PAGE under reducing conditions and visualized by silver stain.
||Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at: In lyophilized state for 1 year (4ºC); After reconstitution under sterile conditions for 3 months (-70ºC).